Gender-Specific Considerations in the Treatment of Mood Disorders in Women Across the Life Cycle

Journal of Clinical Psychiatry

Volumn 64, Issue SUPPL. 15, 2003, Pages 18-29

  Cohen, Lee S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

AGE DISTRIBUTION; CLINICAL TRIAL; COMORBIDITY; CONTRACEPTION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ESTROGEN THERAPY; HORMONAL REGULATION; HUMAN; INVOLUTIONAL DEPRESSION; LIFE CYCLE; MAJOR DEPRESSION; MENTAL HEALTH; META ANALYSIS; MOOD DISORDER; PREDICTION; PREMENSTRUAL DYSPHORIC DISORDER; PREVALENCE; PRIORITY JOURNAL; PUERPERAL DEPRESSION; RATING SCALE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SEX RATIO; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AFFECT; AGED; FEMALE; HUMANS; LIFE CHANGE EVENTS; MIDDLE AGED; MOOD DISORDERS; REPRODUCTION; RISK FACTORS; SEX FACTORS; WOMEN'S HEALTH;

EID: 0345283240     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (142)

1. Kessler RC, McGonagle KA, Swartz M, et al. Sex and depression in the National Comorbidity Survey, 1: lifetime prevalence, chronicity and recurrence. J Affect Disord 1993;29:85-96
2. O'Hara MW, Schlechte JA, Lewis DA, et al. Controlled prospective study of postpartum mood disorders: psychological, environmental, and hormonal variables. J Abnorm Psychol 1991;100:63-73
3. Evans J, Heron J, Francomb H, et al. Cohort study of depressed mood during pregnancy and after childbirth. Br Med J 2001;323:257-260
4. Harlow BL, Cohen LS, Otto MW, et al. Prevalence and predictors of depressive symptoms in older premenopausal women: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry 1999;56:418-424
5. Pincus HA, Pettit AR. The societal costs of chronic major depression. J Clin Psychiatry 2001;62(suppl 6):5-9
6. Wittchen H-U, Hoyer J. Generalized anxiety disorder: nature and course. J Clin Psychiatry 2001;62(suppl 11):15-19
7. Rice DE, Miller LS. Health economics and cost implications of anxiety and other mental disorders in the United States. Br J Psychiatry Suppl 1998:4-9
8. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 1989;262:914-919
9. Weissman MM, Bland R, Joyce PR, et al. Sex differences in rates of depression: cross-national perspectives. J Affect Disord 1993;29:77-84
10. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
11. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996;276:293-299
12. Harrison W, Brumfield MA. Psychopharmacological drug testing in women. In: Jensvold MF, Halbreich U, Hamilton JA, eds. Psychopharmacology and Women: Sex, Gender, and Hormones. Washington, DC: American Psychiatric Press; 1996:371-392
13. Bebbington PE, Brugha T, MacCarthy B, et al. The Camberwell Collaborative Depression Study. I. Depressed probands: adversity and the form of depression. Br J Psychiatry 1988;152:754-765
14. Karp JF, Frank E. Combination therapy and the depressed woman. Depression 1995;3:91-98
15. Rapaport MH, Thompson PM, Kelsoe JR, Jr., et al. Gender differences in outpatient research subjects with affective disorders: a comparison of descriptive variables. J Clin Psychiatry 1995;56:67-72
16. Pajer K. New strategies in the treatment of depression in women. J Clin Psychiatry 1995;56(suppl 2):30-37
17. Burt VK, Stein K. Epidemiology of depression throughout the female life cycle. J Clin Psychiatry 2002;63(suppl 7):9-15
18. Leibenluft E, Hardin TA, Rosenthal NE. Gender differences in seasonal affective disorder. Depression 1995;3:13-19
19. Kornstein SG. The evaluation and management of depression in women across the life span. J Clin Psychiatry 2001;62(suppl 24):11-17
20. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in chronic major and double depression. J Affect Disord 2000;60:1-11
21. Hirschfeld RM, Russell JM. Assessment and treatment of suicidal patients. N Engl J Med 1997;337:910-915
22. Ernst C, Angst J. The Zurich Study. XII. Sex differences in depression: evidence from longitudinal epidemiological data. Eur Arch Psychiatry Clin Neurosci 1992;241:222-230
23. Keitner GI, Ryan CE, Miller IW, et al. 12-month outcome of patients with major depression and comorbid psychiatric or medical illness (compound depression). Am J Psychiatry 1991;148:345-350
24. Winokur G. Depression in the menopause. Am J Psychiatry 1973;130:92-93
25. Hamilton JA, Grant M, Jensvold MF. Sex and treatment of depressions: when does it matter? In: Jensvold MF, Halbreich U, Hamilton JA, eds. Psychopharmacology and Women: Sex, Gender, and Hormones. Washington, DC: American Psychiatric Publishing, Inc; 1996:241-257
26. Raskin A. Age-sex differences in response to antidepressant drugs. J Nerv Ment Dis 1974;159:120-130
27. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000;157:1445-1452
28. Martenyi F, Dossenbach M, Mraz K, et al. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol 2001;11:227-232
29. Amsterdam J, Garcia-Espana F, Fawcett J, et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord 1999;55:11-17
30. Cassano GB, Soares CN, Cohen LS, et al. Menopausal status in major depressive disorder treated with fluoxetine. Presented at the annual meeting of the New Clinical Drug Evaluation Unit; 2003; Boca Raton, Fla
31. Schneider LS, Small GW, Hamilton SH, et al. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial: Fluoxetine Collaborative Study Group. Am J Geriatr Psychiatry 1997;5:97-106
32. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001;62:869-877
33. Thase M, Entsuah R, Cantillon M. Venlafaxine and SSRIs in the treatment of depression: comparison among age and gender variables [abstract]. Presented at the 154th annual meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans, La
34. Endicott J. History, evolution, and diagnosis of premenstrual dysphoric disorder. J Clin Psychiatry 2000;61 (suppl 12):5-8
35. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994
36. Ling FW. Recognizing and treating premenstrual dysphoric disorder in the obstetric, gynecologic, and primary care practices. J Clin Psychiatry 2000;61(suppl 12):9-16
37. Diagnostic and Statistical Manual of Mental Disorders, Text Revision: DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric Association; 2000
38. Yonkers KA. Antidepressants in the treatment of premenstrual dysphoric disorder. J Clin Psychiatry 1997;58(suppl 14):4-10
39. Cohen LS, Soares CN, Otto MW, et al. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women: the Harvard Study of Moods and Cycles. J Affect Disord 2002;70:125-132
40. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: a randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 1997;278:983-988
41. Hylan TR, Sundell K, Judge R. The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom, and France. J Women's Health Gend Based Med 1999;8:1043-1052
42. Schmidt PJ, Nieman LK, Danaceau MA, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998;338:209-216
43. Freeman EW. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder. Eur J Contracept Reprod Health Care 2002;3(suppl 7):27-34
44. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992;36:257-266
45. Management of Premenstrual Syndrome. Kearneysville, WV: American College of Obstetricians and Gynecologists; 2000 April. Report No: Practice Bulletin No. 15
46. Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998;18:390-398
47. Cohen LS, Soares CN, Poitras JR, et al. Short-term use of estradiol as an antidepressant strategy for peri- and postmenopausal women [poster]. Presented at the annual meeting of the American College of Neuropsychopharmacology; Dec 2001; Waikoloa, Hawaii
48. Pearlstein TB, Stone AB. Long-term fluoxetine treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1994;55:332-335
49. Su TP, Schmidt PJ, Danaceau MA, et al. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology 1997;16:346-356.
50. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria: Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995;332:1529-1534
51. Wood SH, Mortola JF, Chan YF, et al. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet Gynecol 1992;80:339-344
52. Stone AB, Pearlstein TB, Brown WA. Fluoxetine in the treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1991;52:290-293
53. Eriksson E, Hedberg MA, Andersch B, et al. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995;12:167-176
54. Pearlstein TB, Halbreich U, Batzar ED, et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000;61:101-109
55. Freeman EW, Rickels K, Arredondo F, et al. Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol 1999;19:3-8
56. Jermain DM, Preece CK, Sykes RL, et al. Luteal phase sertraline treatment for premenstrual dysphoric disorder: results of a double-blind, placebo-controlled, crossover study. Arch Fam Med 1999;8:328-332
57. Young SA, Hurt PH, Benedek DM, et al. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry 1998;59:76-80
58. Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997;58:399-402
59. Freeman EW, Rickels K, Yonkers KA, et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001;98:737-744
60. Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 1993;9:133-145
61. Sundblad C, Modigh K, Andersch B, et al. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand 1992;85:39-47
62. Halbreich U, Bergeron R, Yonkers KA, et al. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002;100:1219-1229
63. Cohen LS, Miner C, Brown E, et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled trial using computerized diaries. Obstet Gynecol 2002;100:435-444
64. McElhatton PR, Garbis HM, Elefant E, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants: a collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 1996;10:285-294.
65. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the newselective serotoninreuptake inhibitors: a prospective controlled multicenter study. JAMA 1998;279:609-610
66. Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999;55:503-508
67. Einarson A, Fatoye B, Sarkar M. et al. Pregnancyoutcome following gestational exposure to venlafaxine: a multicenterprospective controlled study. Am J Psychiatry 2001;158:1728-1730
68. Cohen LS, Heller VL, Bailey JW, et al. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000;48:996-1000
69. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246-2248
70. Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997;89:713-718
71. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-1015
72. Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol 1995;15:417-420
73. Cohen LS, Viguera AC, Lyster AK, et al. Prevalence and predictors of depression during pregnancy [abstract]. Presented at the 155th annual meeting of the American Psychiatric Association; May 2002; Philadelphia, Pa
74. Gotlib IH, Whiffen VE, Mount JH, et al. Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum. J Consult Clin Psychol 1989;57:269-274
75. O'Hara MW. Social support, life events, and depression during pregnancy and the puerperium. Arch Gen Psychiatry 1986;43:569-573
76. Kumar R, Robson KM. A prospective study of emotional disorders in childbearing women. Br J Psychiatry 1984;144:35-47
77. Cohen LS, Rosenbaum JF. Psychotropic drug use during pregnancy: weighing the risks. J Clin Psychiatry 1998;59(suppl 2):18-28
78. Steer RA, Scholl TO, Hediger ML, et al. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol 1992;45:1093-1099
79. Orr ST, Miller CA. Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Epidemiol Rev 1995;17:165-171
80. Hendrick V, Stowe ZN, Altshuler LL, et al. Placental passage of antidepressant medications. Am J Psychiatry 2003;160:993-996
81. Altshuler LL, Cohen LS, Moline ML, et al. The Expert Consensus Guideline Series. Treatment of depression in women. Postgrad Med 2001:1-107
82. Nonacs R, Cohen LS. Depression during pregnancy: diagnosis and treatment options. J Clin Psychiatry 2002;63(suppl 7):24-30
83. Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996;153:592-606
84. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336:258-262
85. Cohen LS, Altshuler LL. Pharmacologic management of psychiatric illness during pregnancy and the postpartum period. In: Psychiatric Clinics of North America, Annual of Drug Therapy. Philadelphia, Pa: Saunders; 1997:21-60
86. Nonacs R, Cohen LS. Postpartum mood disorders: diagnosis and treatment guidelines. J Clin Psychiatry 1998;59(suppl 2):34-40
87. Kendell RE, Chalmers JC, Platz C, Epidemiology of puerperal psychoses. Br J Psychiatry 1987;150:662-673
88. Reich T, Winokur G. Postpartum psychoses in patients with manic depressive disease. J Nerv Ment Dis 1970;151:60-68
89. Davidson J, Robertson E. A follow-up study of post partum illness, 1946-1978. Acta Psychiatr Scand 1985;71:451-457
90. OHara MW, Neunaber DJ, Zekoski EM. Prospective study of postpartum depression: prevalence, course, and predictive factors. J Abnorm Psychol 1984;93:158-171
91. Lyons-Ruth K, Wolfe R, Lyubchik A. Depression and the parenting of young children: making the case for early preventive mental health services. Harv Rev Psychiatry 2000;8:148-153
92. Murray L, Fiori-Cowley A, Hooper R, et al. The impact of postnatal depression and associated adversity on early mother-infant interactions and later infant outcome. Child Dev 1996;67:2512-2526
93. Cogill SR, Caplan HL, Alexandra H, et al. Impact of maternal postnatal depression on cognitive development of young children. Br Med J (Clin Res Ed) 1986;292:1165-1167
94. Wisner KL, Wheeler SB. Prevention of recurrent postpartum major depression. Hosp Community Psychiatry 1994;45:1191-1196
95. O'Hara MW, Stuart S, Gorman LL, et al. Efficacy of interpersonal psychotherapy for postpartum depression. Arch Gen Psychiatry 2000;57:1039-1045
96. Stuart S, O'Hara MW. Interpersonal psychotherapy for postpartum depression: a treatment program. J Psychother Pract Res 1995;4:18-29
97. Appleby L, Warner R, Whitton A, et al. A controlled study of fluoxefine and cognitive-behavioural counselling in the treatment of postnatal depression. Br Med J 1997;314:932-936
98. Stowe ZN, Cassarella J, Landry J, et al. Sertraline in the treatment of women with postpartum major depression. Depression 1995;3:49-55
99. Cohen LS, Viguera AC, Bouffard SM, et al. Venlafaxine in the treatment of postpartum depression. J Clin Psychiatry 2001;62:592-596
100. Wickberg B, Hwang CP. Counselling of postnatal depression: a controlled study on a population based Swedish sample. J Affect Disord 1996;39:209-216
101. Cohen LS, Viguera AC, Collins M, et al. Functional recovery following treatment with venlafaxine for postpartum depression [abstract]. Presented at the annual meeting of the New Clinical Drug Evaluation Unit; May 29, 2001; Phoenix, Az
102. Ahokas A, Aito M, Rimon R. Positive treatment effect of estradiol in postpartum psychosis: a pilot study. J Clin Psychiatry 2000;61:166-169
103. Gregoire AJ, Kumar R, Everitt B, et al. Transdermal oestrogen for 104. Wisner KL, Perel JM, Peindl KS, et al. Prevention of recurrent postpartum depression: a randomized clinical trial. J Clin Psychiatr 2001;62:82-86
104. Gregoire AJ, Kumar R, Everitt B, et al. Transdermal oestrogen for 104. Wisner KL, Perel JM, Peindl KS, et al. Prevention of recurrent postpartum depression: a randomized clinical trial. J Clin Psychiatr 2001;62:82-86
105. Llewellyn A, Stowe ZN. Psychotropic medications in lactation. J Clin Psychiatry 1998;59(suppl 2):41-52
106. Hendrick V, Stowe ZN, Altshuler LL, et al. Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. Biol Psychiatry 2001;50:775-782
107. Birnbaum CS, Cohen LS, Bailey JW, et al. Serum concentrations of antidepressants and benzodiazepines in nursing infants: a case series. Pediatrics 1999;104:e11
108. Wisner KL, Perel JM, Blumer J. Serum sertraline and N-desmethylsertraline levels in breast-feeding mother-infant pairs. Am J Psychiatry 1998;155:690-692
109. Hendrick V, Fukuchi A, Altshuler L, et al. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 2001;179:163-166
110. Stowe ZN, Owens MJ, Landry JC, et al. Sertraline and desmethylsertraline in human breast milk and nursing infants. Am J Psychiatry 1997;154:1255-1260
111. Stowe ZN, Cohen LS, Hostetter A, et al. Paroxetine in human breast milk and nursing infants. Am J Psychiatry 2000;157:185-189
112. Ilett KF, Hacken LP, Dusci LJ, et al. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. Br J Clin Pharmacol 1998;45:459-462
113. Ilett KF, Kristensen JH, Hackett LP, et al. Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants. Br J Clin Pharmacol 2002;53:17-22
114. Burt VK, Altshuler LL, Rasgon N. Depressive symptoms in the perimenopause: prevalence, assessment, and guidelines for treatment. Harv Rev Psychiatry 1998;6:121-132
115. Cooke DJ, Greene JG. Types of life events in relation to symptoms at the climacterium. J Psychosom Res 1981;25:5-11
116. Robinson GE. Psychotic and mood disorders associated with the perimenopausal period: epidemiology, aetiology and management. CNS Drugs 2001;15:175-184
117. Matthews KA, Wing RR, Kuller LH, et al. Influences of natural menopause on psychological characteristics and symptoms of middle-aged healthy women. J Consult Clin Psychol 1990;58:345-351
118. Kaufert PA, Gilbert P, Tate R. The Manitoba Project: a re-examination of the link between menopause and depression. Maturitas 1992;14:143-155
119. Hällström T, Samuelsson S. Mental health in the climacteric: the longitudinal study of women in Gothenburg. Acta Obstet Gynecol Scand Suppl 1985;130:13-18
120. McKinlay SM, Jefferys M. The menopausal syndrome. Br J Prev Soc Med 1974;28:108-115
121. McKinlay JB, McKinlay SM, Brambilla D. The relative contributions of endocrine changes and social circumstances to depression in mid-aged women. J Health Soc Behav 1987;28:345-363
122. Weissman MM, Myers JK. Rates and risks of depressive symptoms in a United States urban community. Acta Psychiatr Scand 1978;57:219-231
123. Kaufert PA, Gilbert P, Hassard T. Researching the symptoms of menopause: an exercise in methodology. Maturitas 1988;10:117-131
124. Mikkelsen A, Holte A. A factor-analytic study of "climacteric" symptoms. Psychiatr Soc Sci 1982;2:35-39
125. Avis NE, Brambilla D, McKinlay SM, et al. A longitudinal analysis of the association between menopause and depression: results from the Massachusetts Women's Health Study. Ann Epidemiol 1994;4:214-220
126. Sagsoz N, Oguzturk O, Bayram M, et al. Anxiety and depression before and after the menopause. Arch Gynecol Obstet 2001;264:199-202
127. Ballinger CB. Psychiatric morbidity and the menopause; screening of general population sample. Br Med J 1975;3:344-346
128. Hunter M. The south-east England longitudinal study of the climacteric and postmenopause. Maturitas 1992;14:117-126
129. Jaszmann L, Van Lith ND, Zaat JCA. The perimenopausal symptoms: the statistical analysis of a survey. Med Gynaecol Sociol 1969;4:268-277
130. Bungay GT, Vessey MP, McPherson CK. Study of symptoms in middle life with special reference to the menopause. Br Med J 1980;281:181-183
131. Collins A, Landgren BM. Reproductive health, use of estrogen and experience of symptoms in perimenopausal women: a population-based study. Maturitas 1994;20:101-111
132. Hunter MS. Psychological and somatic experience of the menopause: a prospective study [corrected]. Psychosom Med 1990;52:357-367
133. Schmidt PJ, Roca CA, Bloch M, et al. The perimenopause and affective disorders. Semin Reprod Endocrinol 1997;15:91-100
134. Coope J. Is oestrogen therapy effective in the treatment of menopausal depression? J R Coll Gen Pract 1981;31:134-140
135. Thomson J. Double blind study on the effect of estrogen on sleep, anxiety and depression in perimenopausal women: preliminary results. Proc R Soc Med 1976;69:829-830
136. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000;183:414-420
137. Soares CN, Almeida OP, Joffe H, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001;58:529-534
138. Rossouw JE, Anderson GL, Prentice RL, et al., for the Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Womens Health Initiative randomized controlled trial. JAMA 2002;288:321-333
139. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: a randomized controlled trial JAMA 2003289:2651-2662
140. Wassertheil-Smoller S, Hendrix S, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Womens Health Initiative, a randomized trial. JAMA 2003;289:2673-2684
141. Fletcher W, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA 2002;288:366-368
142. Yaffe K. Hormone therapy and the brain: deja vu all over again? JAMA 2003;289:2717-2719